To determine the utility of DBPR114 in the treatment of HCC, we first evaluated the in vitro growth inhibition of DBPR114 against a panel of liver cancer cell lines on the basis of histopathology/genetic background including tumor grade, tumor subtypes, p53 alteration status, presence of the hepatitis B virus (HBV) and hepatitis C virus (HCV), and similarity in gene expression profiles compared with the human tumor samples [27]. This evidence concerns the gene TP53 and hepatocellular carcinoma.